Host-Directed Medicine in invasive FUNgal infections

Despite novel treatment options and diagnostic tools, invasive fungal infections are still associated with an unacceptably high mortality and morbidity. Experts believe that a host-directed approach is needed to overcome this clinical challenge. No study to date in invasive fungal infection has integrated a host-directed strategy into a clinical trial. This consortium proposes for the first time a trans-disciplinary approach to identify personalized therapeutic and prophylactic strategies based on host-pathogen factors. We believe that we need such a personalized medicine approach in order to advance the aim of improved outcome in invasive fungal infection, and that, together with the exponential knowledge that has been gained in host-fungal interaction over the last two decades, it is time to move towards proof-of-principle clinical trials that can save lives of patients.

In this project, we aim to identify host-pathogen factors (HPFs) and to dissect their contribution to the development of invasive fungal infection (IFI). Such knowledge is invaluable to guide host-directed immunotherapy and antifungal prophylaxis in patients with IFI in the intensive care unit. Conceptually we believe that immunotherapy guided by host immune status as well as an individualized antimicrobial prophylaxis approach based on host-pathogen factors are the two most promising host-directed medicine approaches that will have the biggest impact on outcome of infectious disease burden in the near future. Both approaches are addressed in HDM-FUN via two independent clinical trials that will result in a unique biobank of clinical samples for host-directed research. Both clinical studies on host-directed medicine are the first of their kind in this area. Hitherto, it is unknown which host-pathogen factors are optimal to stratify patients for immunotherapy or antimicrobial prophylaxis.

 

Latest news

September 10, 2024
4^th HDM-FUN annual meeting
It will take place in Leuven (Belgium) on Oct 1-2, 2024, and will be hosted by KU Leuven.
More information will follow.

---

April 29, 2024
International Symposium on Immunotherapy of Severe Infections
HDM-Fun will attend this scientific event in Kalamata (Greece) on May 16-17, 2024

---

Prof Luigina Romani top female scientists
in the world

Complete ranking for Italy: https://u.garr.it/scCZb
Complete world ranking: https://u.garr.it/4e5fV
Congratulations from @HdmFun

---

Virtual Meetings of HDM-FUN Teams
Short meetings are scheduled for follow up and updates on project activities:

• 12 April, 2021 (from 16.00 to 17.00) and every next month on the Second Monday, until Sep 11, 2023
  Candidemia Team meeting
• 12 April, 2021 (from 11.00 to 12.00) and every next month on the Second Monday, until Sep 11, 2023
  IAPAFLU Team meeting
• 22 March, 2021 (from 16.00 to 17.00)
  Host Team meeting
• 16 March, 2021 (from 16.00 to 17.00)
  Dissemination, Social Sc, and Exploitation team meeting
• 5 March, 2021 (from 11.00 to 12.00)
  Fungal Species Team meeting
• 1 March, 2021 (from 16.00 to 17.00)
  Candidemia Team meeting
• 1 March, 2021 (from 11.00 to 12.00)
  IAPAFLU Team meeting
• 18 February, 2021 (from 16.00 to 17.00)
  Microbiome Team meeting

HDM-FUN Annual Meeting - Siena, Italy
13-14 June 2022
Meeting agenda

Follow up Meeting - online event
2 February 2021
Meeting agenda
List of participants

Kick Off Meeting
12-13 February 2020
Nijmengen, The Netherlands
Meeting agenda
Meeting info

HDM-FUN website online
10 February 2020

 

---

 

HDM-FUN RESERVED AREA

 

---

 

Project details

Full project title
Host-Directed Medicine in invasive FUNgal infections Project

Acronym
HDM-FUN Start date: 1st January 2020

Duration: 5 years

Total EC contribution
€ 9.998.170,00

Coordinator’s contacts
Frank van de Veerdonk
STICHTING KATHOLIEKE UNIVERSITEIT, The Netherlands
Department of Internal Medicine
Frank vandeVeerdonk